We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




IBM Plans to Devise Faster, Less Expensive Sequencing Technology

By LabMedica International staff writers
Posted on 26 Oct 2009
IBM (Armonk, NY, USA) is in the process of slashing the cost of sequencing a genome, now focused on the US$1,000 mark, jumping into a leading position in the biotech revolution.

IBM already has a supercomputer project in position to model biologic processes. More...
Now its combining its supercomputer capacity with its expertise in material science and semiconductors to create a new, much faster sequencing machine that can reduce the cost of mapping the human genome to only $100. Moreover, as scientists continue to systematically clarify the role of genetics in disease, individuals will be able to afford a thorough reading of their risk of disease while drug developers will be able to operate with a clearly devised map to disease targets.

"More and more of biology is becoming an information science, which is very much a business for IBM,” Ajay Royyuru, senior manager for IBM's computational biology center at its Thomas J. Watson Laboratory (Yorktown Heights, NY, USA), recently told the New York Times. Eight years ago sequencing the first genome consumed a billion dollars. The current cost is between $5,000 and $50,000, and rapidly declining.

Related Links:

IBM



Gold Member
STI Test
Vivalytic MG, MH, UP/UU
Online QC Software
Acusera 24•7
New
Automated Urinalysis Solution
UN-9000
New
Automated Coagulation Analyzer
Hemolumi H6
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: For decades, laboratories have adjusted total calcium for albumin, but growing evidence shows these corrections often perform poorly and may cause harm (image credit: iStock)

International Experts Recommend Ending Routine 'Corrected' Calcium Reporting

Interpreting serum calcium can be clinically challenging when albumin levels vary, especially in patients with chronic illness or kidney disease. For decades, laboratories have used formulas to adjust... Read more

Molecular Diagnostics

view channel
Image: The integrated multi-omics approach may help identify bladder cancer patients likely to respond to BCG and those needing alternative or intensified treatment (image credit: iStock)

Multi-Omics Profiling Helps Predict BCG Response and Recurrence in Bladder Cancer

High-risk non–muscle-invasive bladder cancer frequently recurs after therapy, with about 30% of patients relapsing and roughly 10% dying within two years despite tumor resection, surveillance, and Bacillus... Read more

Microbiology

view channel
Image: The findings suggest that people with mpox can transmit the virus even without clinical symptoms (image credit: Adobe Stock)

Study Finds Hidden Mpox Infections May Drive Ongoing Spread

Mpox continues to circulate despite vaccination, and many cases show no known link to a symptomatic partner. The role of people without symptoms has remained uncertain, limiting clarity on how transmission persists.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.